Assembly Biosciences Inc. announced positive results from a Phase 1b clinical study of its investigational capsid assembly modulator, ABI-4334, in patients with HBeAg-negative chronic hepatitis B infection not suppressed on nucleoside analogues. The data, which demonstrated a favorable safety and tolerability profile as well as potent reductions in viral nucleic acids, were presented in a late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held November 7-11, 2025, in Washington, D.C. The study evaluated oral doses of 150 mg and 400 mg of ABI-4334 given once daily over 28 days, with both doses showing multi-log declines in hepatitis B virus DNA and pregenomic RNA. ABI-4334 has not been approved for use, and its safety and efficacy have not yet been established.